• Male or female patients, aged 18 years and older.
• Scheduled to undergo gastric surgery for obesity.
• Able to provide written informed consent before participating in the study.
• Able to communicate adequately with the investigator and to comply with the requirements for the entire study.

• Individuals < 18 years old.
• Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric or other disease that may interfere with the objectives of the study.
• Medications. Opiates and high doses of anticholinergic agents (e.g., amitriptyline greater than 50 mg daily).
• Any other condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study.

Eligibility last updated 9/1/21. Questions regarding updates should be directed to the study team contact.

• 18 to 70 years of age
• Diagnosed with Eosinophilic Esophagitis > than 15 Eos phf and failed to respond to the PPI therapy
• Going through the six food elimination diet or have just completed elimination the six foods: fish, nuts, eggs, soy, wheat, and milk

• Clinical evidence of infectious process potentially contributing to dysphagia (e.g. candidiasis, CMV, herpes)
• Other cause of dysphagia identified at endoscopy (e.g. reflux esophagitis, stricture, web, ring, achalasia, esophageal neoplasm)
• Esophageal minimal diameter < 13 mm on structured barium esophagram

• Adult patients age ≥ 18.
• Undergoing either primary total knee or total hip arthroplasty for a primary underlying diagnosis of osteoarthritis.

• Individuals < 18 years of age.

Eligibility last updated 1/21/22. Questions regarding updates should be directed to the study team contact.

• Primary care clinicians in Rochester/Kasson who complete the pre/posttests, dermoscopy education and conducts skin lesion visits in their practice.  

• Patient refusal for dermoscopy skin lesion photo (skin lesion would then be excluded), dermoscopy image not captured by clinician at visit.

Eligibility last updated 8/18/22. Questions regarding updates should be directed to the study team contact.

• Adults

• Standard exclusion criteria for clinical MRI; e.g. cardiac pacemaker, claustrophobia, an implanted device that has been determined to be MR conditional at 1.5T but not at 3T, anticipated considerable susceptibility artifact from hip prosthesis, etc.
• previous rectal surgery which may preclude tolerance of an endorectal coil

• All adult patients with at least moderate mx/ml-VHD and those with at least moderate single valve disease who had underwent a clinically indicated stress echocardiography study for their VHD prior to the date of IRB submission.
• All adult patients who would be scheduled for a clinically indicated stress echo study in the future (from the date of IRB submission, up to 31st Dec 2022).

• Patients < 18 years old

• Patient at Mayo Clinic – Rochester
• 18 years of age or older

• None

• Patients will be recruited if they already have MRI scans, DXA scans for bone mineral density, and radiographs of the lumbar spine within the last year.
• Three patient groups will be recruited; the first group includes twenty healthy patients with no history of spine disorders or low back pain. The second group includes twenty patients with symptomatic DD, according to the Pfirrmann grading system. The third group includes scoliotic patients (with deformity ≥ 15°).

• Individuals with prior spine, knee, or hip surgery within the last year will be excluded. Patients without imaging data will be excluded. Patients who are not able to perform the physical activities will be excluded. BMI ≥ 35.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/11/23. Questions regarding updates should be directed to the study team contact.

Patients undergoing routine echocardiography

• Subjects with poor apical images
• Patients with congenital heart anomalies
• Patients with multivalvular disease

• Diagnosis of PAH, confirmed by right heart catheterization (mean pulmonary artery pressure of 20 mmHg or greater, pulmonary vascular resistance of 3.0 Woods units or greater, Pulmonary capillary wedge pressure of 15 mmHg or lower).  
• Age ≥ 18 years.
• On PAH-specific therapy which is at stable dosing (i.e., not currently titrating therapy).
• NYHA class II-III symptoms.
• able to complete a six-minute walk test.

• Patients experiencing syncope or exertional syncope.
• Patients not experiencing exertional dyspnea.
• Inability to walk.
• Patients currently in pulmonary rehab or having completed pulmonary rehab within three months (unlikely to improve).

Eligibility last updated 3/14/22. Questions regarding updates should be directed to the study team contact.

•  age >18
• Healthy control volunteers
• Patients with Multiple Sclerosis (Relapsing remitting multiple sclerosis and progressive multiple sclerosis)

Exclusion criteria:

Patients with anxiety or claustrophobia

• Participants undergoing corneal endothelial transplantation because of corneal endothelial dysfunction
• Any age (expected range will be 40-90 in FECD)
• Any sex or race

• Corneal disease other than FECD

• Patients must be considered suitable candidates for a penile prostheses as dictated by the surgeon.
• All stages of PP surgery will be included: primary implants, revision, salvage, infected.
• Patients with prior histories of penile prostheses will have data obtained about their prior devices where available. This information will include the number of devices, penile prostheses-related surgeries, and complications relating to these procedures.
• Each time a new device or new component is placed (revision, salvage) will result in a new data entry point.

• Male or female, ≥ 10 years of age.
• Diagnosis of Hidradenitis Suppurativa (HS) by a dermatologist or practitioner experienced in making a diagnosis of HS.
• Written informed consent (and assent when applicable) obtained from subject or subject’s legal representative and ability for subject to comply with the requirements of the study.
• Immediate family members (for saliva and genetics data).

• Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.

Inclusion Criteria;

• Pre-menopausal (21
  •50 years of age).
• Study group will consist of women seeking hysterectomy for possible adenomyosis adenomyomectomy.
• Controls will consist of women seeking hysterectomy for uterine prolapse or pelvic pain or transgender men prior to androgen treatment and whose pathology shows a uterus < 100 grams with no evidence of adenomyosis, endometriosis, or leiomyomas.

• No ua\se of GnRH analogues, aromatase inhimitors, selective E2 or P4 receptor modulators, oral contraceptives, or immunotherapy within 3 months prior to surgery in any patient.
• No history /confirmation or suspicion of autoimmune disease, fibromyalgia, endometriosis, or leiomyomas in any patient.
• No current or previous history of STDs, pelvic inflammatory disease, endometrial/cervical cancer in any patient.
• Women who do not exhibit menstrual cycles.

Eligibility last updated 10/21/21. Questions regarding updates should be directed to the study team contact.

• Treated with CARPEDIEM as part of standard of care at a participating institution.
• Within the United States.

• Parents/legally authorized representative unable or unwilling to provide consent.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/12/22. Questions regarding updates should be directed to the study team contact.

Inclusion Criteria:

• Must be ≥ 18 years old.
• Individual undergoing elective ureteroscopy and laser lithotripsy for renal or ureteral stones.

• Under 18 years of age.
• Individual cannot be undergoing elective ureteroscopy and laser lithotripsy for renal or ureteral stones.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/20/23. Questions regarding updates should be directed to the study team contact.

• Male and female participants.
• Age 14-20 years old.
• No diagnosed concussion within the past 3 months.
• Participating in organized traveling, high school, or junior hockey. 

• Any medical restriction or injury that would limit the ability to perform a balance screen.
• Diagnosed concussion within the past 3 months.

Inclusion Criteria:

• Patient with pathologically confirmed HCC not amenable to curative resection, transplantation or ablative therapies.
• Have radiographically measurable disease by RECIST.
• Eligible for atezolizumab/bevacizumab front line therapy.
• Male or female with age greater than 18 years, with the capacity and willingness to provide written informed consent.

• Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of the PET scan.
• Patients with higher than the weight/size limitations of PET/CT scanner.

• Any patient undergoing surgery for intralesional resection of neoplasm such as tumors of the spine/extremities or metastatic disease.

• Patients undergoing surgery with an expected blood loss of less than 135cc.
• Provisions for inclusion of minorities: 
  • Subjects will be enrolled prospectively irrespective of their sex/gender, race, and ethnicity in order to improve generalizability.        

Eligibility last updated 2/21/22. Questions regarding updates should be directed to the study team contact.

• Patients diagnosed with or suspected to have a mitochondrial disorder
• Adult carriers of known mitochondrial DNA mutations
• Patients with laboratory analysis indicative of a mitochondrial disorder.
• Medical information and tissue samples are also accepted from deceased individuals who fulfill the above criteria.

• Patients not suspected of having a mitochondrial disorder
• Patients not suspected of carrying a mitochondrial DNA or nuclear DNA mutation that affects mitochondrial function.

• Children aged 14 days
  •17 years.
• At least moderate PARDS, bilateral lung disease, intubated within four days of severe PARDS and no exclusion criteria.

• Children will be excluded if they have any of the following at the start of mechanical ventilation: perinatal related lung disease, congenital diaphragmatic hernia or congenital/acquired diaphragm paralysis, respiratory failure explained by cardiac failure or fluid overload, cyanotic heart disease, cardiomyopathy, unilateral lung disease, primary pulmonary hypertension, status asthmaticus (patient with a severe asthma exacerbation. A previous history of asthma or the use of bronchodilators is NOT an exclusion if the primary disease process is not considered to be obstructive airway disease), obstructive airway disease (e.g., severe airways disease without parenchymal involvement or disease characterized by hypercapnia with FiO2 < 0.30 and/or evidence of increased resistance visible on the flow – time scalar and/or presence of intrinsic PEEP),  bronchiolitis obliterans, post Hematopoietic Stem Cell Transplant, post lung transplant, home ventilator (including noninvasive) dependent, neuromuscular respiratory failure, critical airway (e.g., post laryngotracheal surgery or new tracheostomy) or anatomical obstruction of the lower airway (e.g., mediastinal mass), facial surgery or trauma in previous 15 days, head trauma, intracranial bleeding, unstable spine, femur or pelvic fractures, acute abdominal process/open abdomen, supported on ECMO, previously enrolled in current study, family/medical team deciding not to provide full support, enrolled in any other critical care interventional clinical trial concurrently and known pregnancy.

Eligibility last updated 10/7/21. Questions regarding updates should be directed to the study team contact.

• Adults ≥ 18 years with treatment-naïve biopsy-proven PDA or with findings diagnostic for PDA on baseline imaging (CT, MRI or PET).
• Localized disease expected to undergo surgical resection following NAT.
• ECOG performance status of 0-2.
• Ability to provide informed consent.

• Non-PDA histology on biopsy.
• No baseline PET/CT or PET/MRI.
• Histopathologically proven metastatic PDA.
• Non-FDG avid PDA on baseline PET/CT or PET/MRI.
• Pregnant women.

Eligibility last updated8/25/21.  Questions regarding updates should be directed to the study team contact.

• Male or female, ≥ 18 year of age.
• Group 1: : Papilledema from idiopathic intracranial hypertension and others suspected of elevated intracranial pressure, including obstructive hydrocephalus, or suspected biomechanical changes to the eye, such as choroidal fold.
• Group 2: Patients without raised intracranial pressure.

• Age < 18.
• Pregnancy (self-reported).
• Individuals for whom MR is contraindicated.

Eligibility last updated 10/27/21. Questions regarding updates should be directed to the study team contact.

HF Inclusion Criteria (HeartShare Registry):

• Age ≥ 30 years.
• Prior diagnosis of HF in the EHR (any left ventricular ejection fraction).

Non-HF Group Inclusion Criteria (HeartShare Registry):

• Age ≥ 30 years.
• No known prior diagnosis of HF or use of loop diuretics.
• No known prior history of BNP >100 pg/ml or NTproBNP > 300 pg/ml, if prior laboratory tests are available in the EHR.

Exclusion Criteria (HeartShare Registry):

• For non-HF group: any prior known left ventricular ejection fraction <50%.
• Prior history of solid organ transplantation.
• Prior history of mechanical circulatory support.
• Prior history of non-cardiac cirrhosis.
• Inability to provide written consent to the study.

HFpEF Inclusion for the HeartShare Deep Phenotyping Cohort:

• Age ≥ 30 years.
• Left ventricular ejection fraction ≥ 50% measured by echocardiography.
• Definition of HFpEF: signs and symptoms of HF, NYHA functional class II-IV, and at least one of the following:
  • Elevated BNP (> 100 pg/ml in sinus rhythm or > 300 pg/ml in atrial fibrillation/flutter) or NTproBNP (> 300 pg/ml in sinus rhythm or > 900 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center;
  • Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography);
  • Elevated pulmonary capillary wedge pressure (PCWP) at rest (≥ 15 mmHg) or during exercise (≥ 25 mmHg for supine exercise or PCWP/cardiac output ratio ≥ 2 mmHg/L/min for upright exercise);
  • Elevated H2FPEF score26 (≥ 5) or HFA-PEFF27 score (≥ 5).

Non-HFpEF Group Inclusion Criteria (HeartShare Deep Phenotyping Cohort):

• Age ≥ 30 years.
• Left ventricular ejection fraction ≥ 50% measured by echocardiography.
• No known prior diagnosis of HF or use of diuretics for fluid management.
• No known prior history of BNP > 100 pg/ml or NTproBNP > 300 pg/ml, if prior laboratory tests are available in the EHR.
• BNP < 100 pg/ml or NTproBNP < 300 pg/ml at the time of screening. Choice of BNP or NTproBNP is based on availability at each clinical center.

Exclusion Criteria (HeartShare Deep Phenotyping Cohort):

• Life expectancy estimated to be < 1 year.
• Primary cardiomyopathy (including amyloid, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, or other infiltrative cardiomyopathies) or pulmonary arterial hypertension (WHO Group I, III, or IV pulmonary hypertension).
• Any prior known left ventricular ejection fraction <40%, except if this occurred only in the setting of an acute tachycardia episode (e.g., acute atrial fibrillation).
• Clinically significant valvular heart disease defined as:
  • Moderate to greater aortic stenosis, pulmonic stenosis, or tricuspid stenosis;
  • Any mitral stenosis;
  • Moderate or greater aortic regurgitation;
  • Greater than moderate mitral regurgitation.
• Any planned cardiac surgery or cardiac intervention in the next 3 months.
• Alternative primary reason for symptoms of shortness of breath and exercise intolerance in HFpEF participants in the opinion of the enrolling investigator.
• Cardiac surgery, acute coronary syndrome, percutaneous coronary intervention, stroke, transient ischemic attack, or carotid intervention in the preceding 6 months prior to enrollment.
• Known symptomatic epicardial coronary artery disease that is not revascularized.
• Any non-elective hospitalization in the preceding 2 weeks.
• Prior history of solid organ transplantation.
• Prior history of chronic infection (HIV, hepatitis C, hepatitis B, tuberculosis) unless treated and not clinically active in the opinion of the enrolling investigator.
• Prior history of mechanical circulatory support.
• Prior history of non-cardiac cirrhosis.
• Estimated GFR < 20 ml/min/1.73m^2 or currently on dialysis.
• Any condition that may preclude participation or adherence to the study protocol, in the opinion of the enrolling investigator.
• Inability to provide written consent to the study.
• Current acute decompensated heart failure.
• Currently pregnant.
• Uncontrolled heart rate (> 110 bpm) at time of screening.

Eligibility last updated 5/3/23. Questions regarding updates should be directed to the study team contact.

• Wait listed for liver transplantation with poor 6 MWT

• Age < 18 years
• Recent hospitalization (within 14 days) due to decompensation, variceal bleeding in the previous 1 month
• Large esophageal varices without primary prophylaxis
• Active excessive alcohol intake (in the previous 3 months)
• Current overt uncontrolled hepatic encephalopathy
• Hepatopulmonary syndrome with uncontrolled hypoxia
• Portopulmonary hypertension
• Inability to perform exercise
• Marked symptomatic comorbidities (cardiac, pulmonary, renal)